Literature DB >> 23549007

Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy.

Seung-Gu Yeo1, Dae Yong Kim, Hee Jin Chang, Ji Won Park, Jae Hwan Oh, Byung Chang Kim, Ji Yeon Baek, Sun Young Kim, Tae Hyun Kim.   

Abstract

AIMS AND
BACKGROUND: The pretreatment serum carcinoembryonic antigen (CEA) level is an independent prognostic factor in colorectal cancer. We aimed to investigate the significance of CEA as a prognostic or predictive factor in rectal cancer patients receiving preoperative chemoradiotherapy (CRT). METHODS AND STUDY
DESIGN: In total, 609 patients with locally advanced (cStage II-III) mid to distal rectal cancer who underwent preoperative CRT and radical surgery between 2001 and 2008 were analyzed retrospectively. Predictive factors for pathologic CRT response were determined using multivariate logistic regression. A prognostic factor analysis was performed using the log-rank test and Cox proportional hazards regression.
RESULTS: Elevated CEA levels (>5 ng/mL) were observed in 201 (33.0%) patients at diagnosis. Following preoperative CRT, downstaging (ypStage 0-I) occurred in 255 (41.9%) patients, of whom 88 had pathologic complete tumor regression. Pretreatment CEA was significantly associated with pathologic CRT response in terms of downstaging and tumor regression grade, and was the most relevant predictive factor. After a median follow-up period of 60 months, the 5-year disease-free and overall survival rates were 76.2% and 84.6%, respectively. Prognostic factors independently associated with recurrence or survival included ypStage, circumferential resection margin, and histologic grade.
CONCLUSIONS: In patients with rectal cancer who received preoperative CRT, the pretreatment CEA level was a significant and independent predictor of pathologic CRT response. However, it may not be able to predict long-term outcomes independently of ypStage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23549007     DOI: 10.1177/030089161309900116

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

Review 1.  Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review.

Authors:  Byong Chul Yoo; Seung-Gu Yeo
Journal:  EPMA J       Date:  2017-03-03       Impact factor: 6.543

Review 2.  Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis.

Authors:  Giuseppe Colloca; Antonella Venturino; Pasquale Vitucci
Journal:  Med Oncol       Date:  2017-09-07       Impact factor: 3.064

3.  Preoperative chemoradiotherapy followed by transanal local excision for T3 distal rectal cancer: A case report.

Authors:  Seung-Gu Yeo
Journal:  Exp Ther Med       Date:  2016-02-09       Impact factor: 2.447

Review 4.  Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.

Authors:  Delphine Dayde; Ichidai Tanaka; Rekha Jain; Mei Chee Tai; Ayumu Taguchi
Journal:  Int J Mol Sci       Date:  2017-03-07       Impact factor: 5.923

5.  Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0-I after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Jianyuan Song; Xiaoxue Huang; Zhuhong Chen; Mingqiu Chen; Qingliang Lin; Anchuan Li; Yuangui Chen; Benhua Xu
Journal:  Cancer Manag Res       Date:  2018-08-30       Impact factor: 3.989

6.  Predictive Response Value of Pre- and Postchemoradiotherapy Variables in Rectal Cancer: An Analysis of Histological Data.

Authors:  Marisa D Santos; Cristina Silva; Anabela Rocha; Carlos Nogueira; Eduarda Matos; Carlos Lopes
Journal:  Patholog Res Int       Date:  2016-01-18

7.  Identification of CEA-interacting proteins in colon cancer cells and their changes in expression after irradiation.

Authors:  Byong Chul Yoo; Seung-Gu Yeo
Journal:  Radiat Oncol J       Date:  2017-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.